XBIO Stock Analysis: Buy, Sell, or Hold?
XBIO - Xenetic Biosciences, Inc.
$3.59
0.20 (5.90%)
▲
5d:
+9.45%
30d:
+33.71%
90d:
+22.11%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When XBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: XBIO is 10.1% above its trading range ($3.26). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: XBIO is 10.1% above its trading range ($3.26). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: XBIO is currently trading at $3.59, which is considered extended relative to its 30-day fair value range of $2.60 to $3.26.
Technical Outlook: Technically, XBIO is in a downtrend. Immediate support is located at $3.02, while resistance sits at $3.73. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: XBIO scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $40.00 (+1079.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XBIO is in a downtrend. Immediate support is located at $3.02, while resistance sits at $3.73. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: XBIO scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $40.00 (+1079.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.60 -
$3.26
Company Quality Score
30/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+10.1% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.9%)
- BULLISH: Trading 1079.9% below Wall St target ($40.00)
- WARNING: Composite score 30/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.60 -
$3.26
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.02
Resistance Level
$3.73
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.97
Wall Street Target
$40.00
(+1079.9%)
Revenue Growth (YoY)
12.0%
Profit Margin
-75.9%
Share & Embed Analysis
Last updated: August 24, 2026 7:00 AM ET
Data refreshes hourly during market hours. Next update: 8:00 AM
Data refreshes hourly during market hours. Next update: 8:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XBIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$560 | 30 SELL |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
